Medical Device Labeling & Information Services

Medical device labeling requirements vary by market, but generally include accurate device identification, intended use, manufacturer details, warnings, contraindications, storage conditions, and any mandatory symbols or UDI elements. Labels and IFUs must also be consistent with the technical documentation and approved claims. Regulators expect labeling to be truthful, complete, and supported by evidence, not just commercially appealing.

For medical devices in Australia, the TGA requires compliance with the Therapeutic Goods Act 1989, the Medical Devices Regulations 2002, and applicable labeling rules such as TGO 91. Requirements typically include ARTG inclusion, conformity assessment evidence, Essential Principles compliance, and market-appropriate labeling and IFUs. Labels prepared for FDA or EU MDR often need targeted review before they are suitable for Australia.

Labeling is one of the first places regulators check for consistency between your claims, intended use, risk controls, and technical documentation. If labels or IFUs contain unsupported statements, omit mandatory content, or conflict with the submission file, they can trigger deficiencies, delays, or broader credibility concerns. Strong labeling helps reinforce the overall compliance story of the device.

A labeling review commonly covers product labels, outer packaging, Instructions for Use, patient information, symbols, UDI content, promotional claims that may affect regulatory positioning, and cross-references to technical documentation. Depending on the market, reviewers may also assess language requirements, implant cards, electronic labeling considerations, and consistency with risk management, clinical evidence, and submission summaries.

A core global label can often be developed, but a single version rarely works unchanged across all markets. FDA, EU MDR, and TGA each have distinct expectations for mandatory statements, symbols, language, UDI presentation, and claim boundaries. The most effective approach is usually a harmonized base label supported by market-specific adaptations that preserve consistency while meeting local requirements.

Labeling issues can delay approval by creating inconsistencies that force regulators to question the intended use, safety messaging, or evidence supporting the device. Missing warnings, unclear indications, unsupported performance claims, or incorrect symbols often lead to deficiency letters or requests for clarification. Fixing these late in the process can also require updates to risk files, clinical documents, and submission sections.

Yes, UDI is often a critical part of labeling review. Depending on the target market, the review may assess whether UDI elements are required, correctly formatted, properly placed, and consistent with registration or submission data. UDI compliance also needs to align with packaging levels, device identification records, and any applicable database or authority-specific implementation requirements.

Labeling should be reviewed early enough to influence design outputs, risk controls, usability considerations, and submission planning—not just at the final artwork stage. An early review helps ensure intended use language, warnings, symbols, and user instructions are built into the broader regulatory strategy. A second detailed review is usually valuable before submission, audit, or commercial release.